Top Markets
#1 QuantixAI QuantixAI +63.77%
#2 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +38.02%
#3 MowCat MowCat +30.40%
#4 MarsCoin MarsCoin +29.74%
#5 UnifAI Network UnifAI Network +29.68%
#6 GEKKO GEKKO +27.75%
#7 Prom Prom +25.87%
#8 Kinesis Silver Kinesis Silver +20.73%
#9 Versatize Coin Versatize Coin +16.66%
#10 Derive Derive +15.71%
Coin of the day
QuantixAI QuantixAI
Settings
Language
ENGLISH
Currency
USD
Theme
Pharmosa Biopharm Inc. Pharmosa Biopharm Inc.

Pharmosa Biopharm Inc.

6875
Rank in Stocks #20403
Pharmosa Biopharm Inc., a biotechnology firm based in Taiwan, specializes in... Pharmosa Biopharm Inc., a biotechnology firm based in Taiwan, specializes in the development of pharmaceutical products. Its current pipeline includes two key candidates: L606 and L608. L606 is an investigational inhalation/device combination therapy designed to treat both pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease. Similarly, L608 is another inhalation-based therapy, paired with a device, aimed at addressing pulmonary vascular disease. The company, which was established in 2000, originally operated under the name Pharmosa Limited before adopting its current name, Pharmosa Biopharm Inc., in October 2016. Its main offices are located in Taipei City, Taiwan.
Share Price
$1.02
Market Cap
$131.45M
Change (1 day)
-0.62%
Change (1 year)
-37.92%
Country
TW
Trade Pharmosa Biopharm Inc. (6875)

Category

Healthcare
Revenue for Pharmosa Biopharm Inc. (6875)
Revenue in Aug 2026 TTM: 0
According to Pharmosa Biopharm Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Pharmosa Biopharm Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH